Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease

PREVENT-COVID Study Group

doi:10.1053/j.gastro.2021.06.016

Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease

PREVENT-COVID Study Group

Research output: Contribution to journal › Short survey › peer-review

Original language	English (US)
Pages (from-to)	1340-1343.e2
Journal	Gastroenterology
Volume	161
Issue number	4
DOIs	https://doi.org/10.1053/j.gastro.2021.06.016
State	Published - Oct 2021

ASJC Scopus subject areas

Hepatology
Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1053/j.gastro.2021.06.016

Cite this

@article{e1b003e22416403d885c017a6d743062,

title = "Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease",

author = "{PREVENT-COVID Study Group} and Kappelman, {Michael D.} and Weaver, {Kimberly N.} and Margie Boccieri and Ann Firestine and Xian Zhang and Long, {Millie D.} and K. Chun and M. Fernando and M. Zikry and X. Dai and R. Watkins and J. Adler and Dubinsky, {M. C.} and A. Kastl and A. Bousvaros and Strople, {J. A.} and Cross, {R. K.} and Higgins, {P. D.R.} and R. Ungaro and M. Bewtra and E. Bellaguarda and Farraye, {F. A.}",

note = "Funding Information: Conflicts of interest These authors disclose the following: Michael D. Kappelman has consulted for Abbvie , Janssen, Pfizer , and Takeda; is a shareholder in Johnson & Johnson; and has received research support from Pfizer , Takeda, Janssen, Abbvie , Lilly , Genentech, Boehringer Ingelheim, Bristol Myers Squibb , Celtrion, and Arenapharm. Millie Long has received research/grants from Pfizer Inc and has consulted for AbbVie Inc, Bristol-Myers Squibb Company, Calibr, Eli Lilly and Company , Genentech, Inc, Gilead Sciences , Inc, Janssen Pharmaceuticals , Inc, Pfizer Inc, Roche , Takeda Pharmaceuticals U.S.A. , Inc, TARGET PharmaSolutions, Inc, and Theravance Biopharma. These authors from the PREVENT-COVID Study Group disclose the following: JA has consulted for Janssen and has received research support from The Gary and Rachel Glick Charitable Fund, Shaevsky Family Research Fund for Crohn's Disease, the Crohn{\textquoteright}s & Colitis Foundation, and The Leona M. and Harry B. Helmsley Charitable Trust. MCD has received consultant fees from Abbvie , Arena, Bristol Myers Squibb , Celgene, Gilead, Janssen, Pfizer , Prometheus Labs, and Takeda; grant support from Abbvie and Prometheus Labs; and license fees from Takeda. AB has been a subinvestigator on trials for Prometheus, Janssen, Abbvie, Takeda, Buhlmann, Arena, and Eli Lilly in the past 36 months and has consulted for Arena, Tekeda, Best Doctors, and Eli Lilly. JAS has consulted for Janssen and has received research support from The Gary and Rachel Glick Charitable Fund, Shaevsky Family Research Fund for Crohn's Disease, the Crohn{\textquoteright}s & Colitis Foundation, and The Leona M. and Harry B. Helmsley Charitable Trust. RKC has participated in advisory boards and has consulted for Abbvie, Bristol Myers Squibb, Janssen, LabCorp, Pfizer, Samsung Bioepis, and Takeda. PDRH has consulted for Abbvie , Pfizer , and Takeda and has received grant support from the National Institutes of Health , CCF, Abbvie , Pfizer , Takeda, Genentech, Eli Lilly , Arena, and the Rainin Foundation. RCU has served as an advisory board member or consultant for AbbVie , Bristol Myers Squibb , Eli Lilly , Janssen, Pfizer , and Takeda and has received research support from AbbVie , Boehringer Ingelheim, and Pfizer . RCU is funded by a National Institutes of Health Career Development Award (K23KD111995-01A1). MB discloses research funding from Janssen, GlaxoSmithKline , and Takeda; has served as a consultant for Janssen, AbbVie , BMS, and Pfizer; and has received honorarium for participation in a CME program sponsored by AbbVie . EB has consulted for Abbvie, Pfizer, and Bristol Myers Squibb. FAF is a consultant for Arena, BMS, Braintree Labs, Gilead, GI Reviewers, Innovation Pharmaceuticals, Iterative Scopes, Janssen, Pfizer, and Sebela and sits on a Data Safety Monitoring Board for Lilly and Theravance. The remaining authors disclose no conflicts. Funding Information: Funding This research was funded by the Helmsley Charitable Trust . Funding Information: Conflicts of interest These authors disclose the following: Michael D. Kappelman has consulted for Abbvie, Janssen, Pfizer, and Takeda; is a shareholder in Johnson & Johnson; and has received research support from Pfizer, Takeda, Janssen, Abbvie, Lilly, Genentech, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion, and Arenapharm. Millie Long has received research/grants from Pfizer Inc and has consulted for AbbVie Inc, Bristol-Myers Squibb Company, Calibr, Eli Lilly and Company, Genentech, Inc, Gilead Sciences, Inc, Janssen Pharmaceuticals, Inc, Pfizer Inc, Roche, Takeda Pharmaceuticals U.S.A., Inc, TARGET PharmaSolutions, Inc, and Theravance Biopharma. These authors from the PREVENT-COVID Study Group disclose the following: JA has consulted for Janssen and has received research support from The Gary and Rachel Glick Charitable Fund, Shaevsky Family Research Fund for Crohn's Disease, the Crohn's & Colitis Foundation, and The Leona M. and Harry B. Helmsley Charitable Trust. MCD has received consultant fees from Abbvie, Arena, Bristol Myers Squibb, Celgene, Gilead, Janssen, Pfizer, Prometheus Labs, and Takeda; grant support from Abbvie and Prometheus Labs; and license fees from Takeda. AB has been a subinvestigator on trials for Prometheus, Janssen, Abbvie, Takeda, Buhlmann, Arena, and Eli Lilly in the past 36 months and has consulted for Arena, Tekeda, Best Doctors, and Eli Lilly. JAS has consulted for Janssen and has received research support from The Gary and Rachel Glick Charitable Fund, Shaevsky Family Research Fund for Crohn's Disease, the Crohn's & Colitis Foundation, and The Leona M. and Harry B. Helmsley Charitable Trust. RKC has participated in advisory boards and has consulted for Abbvie, Bristol Myers Squibb, Janssen, LabCorp, Pfizer, Samsung Bioepis, and Takeda. PDRH has consulted for Abbvie, Pfizer, and Takeda and has received grant support from the National Institutes of Health, CCF, Abbvie, Pfizer, Takeda, Genentech, Eli Lilly, Arena, and the Rainin Foundation. RCU has served as an advisory board member or consultant for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, and Takeda and has received research support from AbbVie, Boehringer Ingelheim, and Pfizer. RCU is funded by a National Institutes of Health Career Development Award (K23KD111995-01A1). MB discloses research funding from Janssen, GlaxoSmithKline, and Takeda; has served as a consultant for Janssen, AbbVie, BMS, and Pfizer; and has received honorarium for participation in a CME program sponsored by AbbVie. EB has consulted for Abbvie, Pfizer, and Bristol Myers Squibb. FAF is a consultant for Arena, BMS, Braintree Labs, Gilead, GI Reviewers, Innovation Pharmaceuticals, Iterative Scopes, Janssen, Pfizer, and Sebela and sits on a Data Safety Monitoring Board for Lilly and Theravance. The remaining authors disclose no conflicts.Funding This research was funded by the Helmsley Charitable Trust.",

year = "2021",

month = oct,

doi = "10.1053/j.gastro.2021.06.016",

language = "English (US)",

volume = "161",

pages = "1340--1343.e2",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease

AU - PREVENT-COVID Study Group

AU - Kappelman, Michael D.

AU - Weaver, Kimberly N.

AU - Boccieri, Margie

AU - Firestine, Ann

AU - Zhang, Xian

AU - Long, Millie D.

AU - Chun, K.

AU - Fernando, M.

AU - Zikry, M.

AU - Dai, X.

AU - Watkins, R.

AU - Adler, J.

AU - Dubinsky, M. C.

AU - Kastl, A.

AU - Bousvaros, A.

AU - Strople, J. A.

AU - Cross, R. K.

AU - Higgins, P. D.R.

AU - Ungaro, R.

AU - Bewtra, M.

AU - Bellaguarda, E.

AU - Farraye, F. A.

N1 - Funding Information: Conflicts of interest These authors disclose the following: Michael D. Kappelman has consulted for Abbvie , Janssen, Pfizer , and Takeda; is a shareholder in Johnson & Johnson; and has received research support from Pfizer , Takeda, Janssen, Abbvie , Lilly , Genentech, Boehringer Ingelheim, Bristol Myers Squibb , Celtrion, and Arenapharm. Millie Long has received research/grants from Pfizer Inc and has consulted for AbbVie Inc, Bristol-Myers Squibb Company, Calibr, Eli Lilly and Company , Genentech, Inc, Gilead Sciences , Inc, Janssen Pharmaceuticals , Inc, Pfizer Inc, Roche , Takeda Pharmaceuticals U.S.A. , Inc, TARGET PharmaSolutions, Inc, and Theravance Biopharma. These authors from the PREVENT-COVID Study Group disclose the following: JA has consulted for Janssen and has received research support from The Gary and Rachel Glick Charitable Fund, Shaevsky Family Research Fund for Crohn's Disease, the Crohn’s & Colitis Foundation, and The Leona M. and Harry B. Helmsley Charitable Trust. MCD has received consultant fees from Abbvie , Arena, Bristol Myers Squibb , Celgene, Gilead, Janssen, Pfizer , Prometheus Labs, and Takeda; grant support from Abbvie and Prometheus Labs; and license fees from Takeda. AB has been a subinvestigator on trials for Prometheus, Janssen, Abbvie, Takeda, Buhlmann, Arena, and Eli Lilly in the past 36 months and has consulted for Arena, Tekeda, Best Doctors, and Eli Lilly. JAS has consulted for Janssen and has received research support from The Gary and Rachel Glick Charitable Fund, Shaevsky Family Research Fund for Crohn's Disease, the Crohn’s & Colitis Foundation, and The Leona M. and Harry B. Helmsley Charitable Trust. RKC has participated in advisory boards and has consulted for Abbvie, Bristol Myers Squibb, Janssen, LabCorp, Pfizer, Samsung Bioepis, and Takeda. PDRH has consulted for Abbvie , Pfizer , and Takeda and has received grant support from the National Institutes of Health , CCF, Abbvie , Pfizer , Takeda, Genentech, Eli Lilly , Arena, and the Rainin Foundation. RCU has served as an advisory board member or consultant for AbbVie , Bristol Myers Squibb , Eli Lilly , Janssen, Pfizer , and Takeda and has received research support from AbbVie , Boehringer Ingelheim, and Pfizer . RCU is funded by a National Institutes of Health Career Development Award (K23KD111995-01A1). MB discloses research funding from Janssen, GlaxoSmithKline , and Takeda; has served as a consultant for Janssen, AbbVie , BMS, and Pfizer; and has received honorarium for participation in a CME program sponsored by AbbVie . EB has consulted for Abbvie, Pfizer, and Bristol Myers Squibb. FAF is a consultant for Arena, BMS, Braintree Labs, Gilead, GI Reviewers, Innovation Pharmaceuticals, Iterative Scopes, Janssen, Pfizer, and Sebela and sits on a Data Safety Monitoring Board for Lilly and Theravance. The remaining authors disclose no conflicts. Funding Information: Funding This research was funded by the Helmsley Charitable Trust . Funding Information: Conflicts of interest These authors disclose the following: Michael D. Kappelman has consulted for Abbvie, Janssen, Pfizer, and Takeda; is a shareholder in Johnson & Johnson; and has received research support from Pfizer, Takeda, Janssen, Abbvie, Lilly, Genentech, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion, and Arenapharm. Millie Long has received research/grants from Pfizer Inc and has consulted for AbbVie Inc, Bristol-Myers Squibb Company, Calibr, Eli Lilly and Company, Genentech, Inc, Gilead Sciences, Inc, Janssen Pharmaceuticals, Inc, Pfizer Inc, Roche, Takeda Pharmaceuticals U.S.A., Inc, TARGET PharmaSolutions, Inc, and Theravance Biopharma. These authors from the PREVENT-COVID Study Group disclose the following: JA has consulted for Janssen and has received research support from The Gary and Rachel Glick Charitable Fund, Shaevsky Family Research Fund for Crohn's Disease, the Crohn's & Colitis Foundation, and The Leona M. and Harry B. Helmsley Charitable Trust. MCD has received consultant fees from Abbvie, Arena, Bristol Myers Squibb, Celgene, Gilead, Janssen, Pfizer, Prometheus Labs, and Takeda; grant support from Abbvie and Prometheus Labs; and license fees from Takeda. AB has been a subinvestigator on trials for Prometheus, Janssen, Abbvie, Takeda, Buhlmann, Arena, and Eli Lilly in the past 36 months and has consulted for Arena, Tekeda, Best Doctors, and Eli Lilly. JAS has consulted for Janssen and has received research support from The Gary and Rachel Glick Charitable Fund, Shaevsky Family Research Fund for Crohn's Disease, the Crohn's & Colitis Foundation, and The Leona M. and Harry B. Helmsley Charitable Trust. RKC has participated in advisory boards and has consulted for Abbvie, Bristol Myers Squibb, Janssen, LabCorp, Pfizer, Samsung Bioepis, and Takeda. PDRH has consulted for Abbvie, Pfizer, and Takeda and has received grant support from the National Institutes of Health, CCF, Abbvie, Pfizer, Takeda, Genentech, Eli Lilly, Arena, and the Rainin Foundation. RCU has served as an advisory board member or consultant for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, and Takeda and has received research support from AbbVie, Boehringer Ingelheim, and Pfizer. RCU is funded by a National Institutes of Health Career Development Award (K23KD111995-01A1). MB discloses research funding from Janssen, GlaxoSmithKline, and Takeda; has served as a consultant for Janssen, AbbVie, BMS, and Pfizer; and has received honorarium for participation in a CME program sponsored by AbbVie. EB has consulted for Abbvie, Pfizer, and Bristol Myers Squibb. FAF is a consultant for Arena, BMS, Braintree Labs, Gilead, GI Reviewers, Innovation Pharmaceuticals, Iterative Scopes, Janssen, Pfizer, and Sebela and sits on a Data Safety Monitoring Board for Lilly and Theravance. The remaining authors disclose no conflicts.Funding This research was funded by the Helmsley Charitable Trust.

PY - 2021/10

Y1 - 2021/10

UR - http://www.scopus.com/inward/record.url?scp=85112015693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85112015693&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2021.06.016

DO - 10.1053/j.gastro.2021.06.016

M3 - Short survey

C2 - 34144046

AN - SCOPUS:85112015693

VL - 161

SP - 1340-1343.e2

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 4

ER -

Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this